These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 32305222)

  • 1. Prognostic Usefulness of Myocardial Work in Patients With Heart Failure and Reduced Ejection Fraction Treated by Sacubitril/Valsartan.
    Bouali Y; Donal E; Gallard A; Laurin C; Hubert A; Bidaut A; Leclercq C; Galli E
    Am J Cardiol; 2020 Jun; 125(12):1856-1862. PubMed ID: 32305222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction.
    Martens P; Beliën H; Dupont M; Vandervoort P; Mullens W
    Cardiovasc Ther; 2018 Aug; 36(4):e12435. PubMed ID: 29771478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial clinical experience with the first drug (sacubitril/valsartan) in a new class - angiotensin receptor neprilysin inhibitors in patients with heart failure with reduced left ventricular ejection fraction in Poland.
    Kałużna-Oleksy M; Kolasa J; Migaj J; Pawlak A; Lelonek M; Nessler J; Straburzyńska-Migaj E
    Kardiol Pol; 2018; 76(2):381-387. PubMed ID: 29192956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
    Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
    Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sacubitril/valsartan improves both functional and echocardiographic parameters in patients with chronic heart failure with reduced ejection fraction.
    Cosentino ER; Degli Esposti D; Miceli R; Bentivenga C; Landolfo M; Fg Cicero A; Berardi E; Spinardi L; Magri G; Dugato V; Borghi C
    Curr Med Res Opin; 2019 Mar; 35(sup1):9-12. PubMed ID: 30864900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of angiotensin receptor neprilysin inhibition on pulmonary arterial stiffness in heart failure with reduced ejection fraction.
    Yenerçağ M; Arslan U; Dereli S; Çoksevim M; Doğduş M; Kaya A
    Int J Cardiovasc Imaging; 2021 Jan; 37(1):165-173. PubMed ID: 32815051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world treatment switching to sacubitril/valsartan in patients with heart failure with reduced ejection fraction: A cohort study.
    Ganesananthan S; Shah N; Shah P; Elsayed H; Phillips J; Parkes A; Morgan A; Yousef Z
    Open Heart; 2020 Oct; 7(2):. PubMed ID: 33020255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics and Healthcare Utilization Among Veterans Treated for Heart Failure With Reduced Ejection Fraction Who Switched to Sacubitril/Valsartan.
    Mohanty AF; Levitan EB; Dodson JA; Vardeny O; King JB; LaFleur J; He T; Patterson OV; Alba PR; Russo PA; Choi ME; Bress AP
    Circ Heart Fail; 2019 Nov; 12(11):e005691. PubMed ID: 31718321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effectiveness of Sacubitril-Valsartan Combination Therapy Compared With Enalapril for the Treatment of Heart Failure With Reduced Ejection Fraction.
    King JB; Shah RU; Bress AP; Nelson RE; Bellows BK
    JACC Heart Fail; 2016 May; 4(5):392-402. PubMed ID: 27039128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure.
    Solomon SD; Vaduganathan M; L Claggett B; Packer M; Zile M; Swedberg K; Rouleau J; A Pfeffer M; Desai A; Lund LH; Kober L; Anand I; Sweitzer N; Linssen G; Merkely B; Luis Arango J; Vinereanu D; Chen CH; Senni M; Sibulo A; Boytsov S; Shi V; Rizkala A; Lefkowitz M; McMurray JJV
    Circulation; 2020 Feb; 141(5):352-361. PubMed ID: 31736342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness of Switching Patients With Heart Failure and Reduced Ejection Fraction to Sacubitril/Valsartan: The Australian Perspective.
    Chin KL; Zomer E; Wang BH; Liew D
    Heart Lung Circ; 2020 Sep; 29(9):1310-1317. PubMed ID: 32303468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Patients with Heart Failure to Determine Eligibility for Treatment with Sacubitril/Valsartan: Insights from a Veterans Administration Healthcare System.
    Han J; Chung F; Nguyen QL; Mody FV; Jackevicius CA
    Pharmacotherapy; 2019 Nov; 39(11):1053-1059. PubMed ID: 31498903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recovery of left ventricular dysfunction after sacubitril/valsartan: predictors and management.
    Chang HY; Chen KC; Fong MC; Feng AN; Fu HN; Huang KC; Chong E; Yin WH
    J Cardiol; 2020 Mar; 75(3):233-241. PubMed ID: 31563433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sacubitril/valsartan for heart failure with reduced ejection fraction: A first real-life observational study in Poland.
    Lelonek M; Wiśniowska-Śmiałek S; Rubiś P; Nowakowska I; Pawlak A
    Adv Clin Exp Med; 2021 Jan; 30(1):67-75. PubMed ID: 33529509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the Efficacy and Safety of Sacubitril/Valsartan versus Ramipril in Patients With ST-Segment Elevation Myocardial Infarction.
    Rezq A; Saad M; El Nozahi M
    Am J Cardiol; 2021 Mar; 143():7-13. PubMed ID: 33417876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myocardial work improvement after sacubitril-valsartan therapy: a new echocardiographic parameter for a new treatment.
    Valentim Gonçalves A; Galrinho A; Pereira-da-Silva T; Branco L; Rio P; Timóteo AT; Abreu J; Soares RM; Feliciano J; Moreira RI; Ferreira RC
    J Cardiovasc Med (Hagerstown); 2020 Mar; 21(3):223-230. PubMed ID: 31990748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolution of functional class, biochemical and echocardiographic parameters and clinical outcomes after sacubitril/valsartan initiation in daily practice.
    Morillas-Climent H; Seller-Moya J; Vicedo-López Á; Galcerá-Jornet E; Alania-Torres E; Rodríguez-Pichardo Y; Larumbe-Rodríguez A; Valle-Muñoz A
    J Comp Eff Res; 2019 Jul; 8(9):685-697. PubMed ID: 31290687
    [No Abstract]   [Full Text] [Related]  

  • 18. Cost-effectiveness of sacubitril/valsartan in chronic heart-failure patients with reduced ejection fraction.
    Ademi Z; Pfeil AM; Hancock E; Trueman D; Haroun RH; Deschaseaux C; Schwenkglenks M
    Swiss Med Wkly; 2017; 147():w14533. PubMed ID: 29185253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFrEF.
    Zile MR; O'Meara E; Claggett B; Prescott MF; Solomon SD; Swedberg K; Packer M; McMurray JJV; Shi V; Lefkowitz M; Rouleau J
    J Am Coll Cardiol; 2019 Feb; 73(7):795-806. PubMed ID: 30784673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Echocardiographic evaluation of the effects of sacubitril-valsartan on vascular properties in heart failure patients.
    Karagodin I; Kalantari S; Yu DB; Kim G; Sayer G; Addetia K; Tayazime S; Weinert L; Yamat M; Uriel N; Lang R; Mor-Avi V
    Int J Cardiovasc Imaging; 2020 Feb; 36(2):271-278. PubMed ID: 31583499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.